Despite breakthroughs in medical sciences, drug development remains a time-consuming, expensive, challenging, and inefficient process with a high failure rate for novel therapeutic discoveries. Bioinformatics analysis can speed up drug target identification, drug candidate screening, and refining, but it can also help characterise adverse effects and anticipate drug resistance. Integrated genomics, proteomics, and bioinformatics have resulted in potent new tactics for resolving numerous biochemical problems and establishing new methodologies that result in new biomedical products. As a result, a new research trend emerged to demonstrate the mechanism of therapeutic action, forecast drug resistance, and uncover biomarkers for various disorders. The development of new medications is a complicated procedure. There are two basic approaches to drug design: ligand-based drug design and structure-based drug design. The study of protein structure and function was essential for drug development. Current techniques based on combinatorial approaches such as proteomics, genomics, bioinformatics, molecular docking, and mass spectrometry were applied. This article provides an overview of the combinatorial techniques of proteomics, genomics, and bioinformatics that aid in understanding the drug-creation process.

Background: Nowadays, biomedical research has been focusing on the design and development of new drug delivery systems that provide efficient drug targeting. The molecularly imprinted polymers (MIPs) have attracted wide interest and play an indispensable role as a drug carrier. Drug delivery systems based on MIPs have been frequently cited in the literature. They are cross-linked polymers that contain binding sites according to the complementary structure of the template molecules. They possess distinctive features of structure predictability and site recognition specificity. Versatile applications of MIPs include purification, biosensing, bioseparation, artificial antibodies, and drug delivery. An ideal MIPs should include features such as biocompatibility, biodegradability, and stability. Objective: In this article, we elaborate the historic growth, synthesis, and preparation of different MIPs and present an updated summary of recent advances in the development of new drug delivery system which are based on this technique. Their potential to deliver drugs in a controlled and targeted manner will also be discussed. Conclusion: MIPs possess unique advantages, such as lower toxicity, and fewer side effects, and good therapeutic potential. They offer administration of drugs by different routes, i.e., oral, ocular or transdermal. Despite several advantages, biomedical companies are hesitant to invest in MIPs based drug delivery system due to the limited availability of chemical compounds.

Nanocomposites have become a promising approach for drug delivery in the pharmaceutical field due to several benefits and current research development. Polymer nanocomposites (PNCs) are blends of nanomaterials and polymers with at least one-dimensional structure and one component in the sub-100 nm range. By incorporating nanoparticles into the polymer matrix, it is feasible to create a new class of given characteristics. Nano-clay (a type of nanocomposite) is mainly used for the controlled release of therapeutics in various disease conditions. Nanocomposites are promising drug delivery systems due to several advantages, including surface and rheological characteristics. Considering physical and chemical properties, nanocomposites are divided into two different components. Polymer-fabricated nanocomposites are potentially used in multi-particulate systems, which results in a controlled drug release profile with improved mechanical integrity. Nanotechnology-based drug delivery nanocomposites offer an improved half-life, greater biocompatibility, minimum immunogenicity, site-specific targeting, and avoid membrane barriers. Specifically, one-dimensional (1D) nanocomposites show promising responses in theranostics due to improved surface area-to-volume ratios that offer specific targeting, improved encapsulation efficiency, and susceptibility to biomolecules.

Iridoids are secondary plant metabolites that are multitarget compounds active against various diseases. Iridoids are structurally classified into iridoid glycosides and non-glycosidic iridoids according to the presence or absence of intramolecular glycosidic bonds; additionally, iridoid glycosides can be further subdivided into carbocyclic iridoids and secoiridoids. These monoterpenoids belong to the cyclopentan[c]-pyran system, which has a wide range of biological activities, including antiviral, anticancer, antiplasmodial, neuroprotective, anti-thrombolytic, antitrypanosomal, antidiabetic, hepatoprotective, anti-oxidant, antihyperlipidemic and anti-inflammatory properties. The basic chemical structure of iridoids in plants (the iridoid ring scaffold) is biosynthesized in plants by the enzyme iridoid synthase using 8-oxogeranial as a substrate. With advances in phytochemical research, many iridoid compounds with novel structure and outstanding activity have been identified in recent years. Biologically active iridoid derivatives have been found in a variety of plant families, including Plantaginaceae, Rubiaceae, Verbenaceae, and Scrophulariaceae. Iridoids have the potential of modulating many biological events in various diseases. This review highlights the multitarget potential of iridoids and includes a compilation of recent publications on the pharmacology of iridoids. Several in vitro and in vivo models used, along with the results, are also included in the paper. This paper's systematic summary was created by searching for relevant iridoid material on websites such as Google Scholar, PubMed, SciFinder Scholar, Science Direct, and others.The compilation will provide the researchers with a thorough understanding of iridoid and its congeners, which will further help in designing a large number of potential compounds with a strong impact on curing various diseases.

No abstract